Splash Beverage Group entered a strategic collaboration with Lupvindol Biosciences to advance CannEpil as an FDA-regulated veterinary pharmaceutical for companion-animal oncology and chronic pain management. Lupvindol will lead scientific, product-development, and regulatory activities under the Investigational New Animal Drug process toward potential Conditional Approval. Splash retains ownership of resulting data and intellectual property while providing milestone-based funding and leading commercialization strategy. The company operates in the cannabinoid health, wellness, and biopharmaceutical industry.
